Belimumab Maintenance Fails to Delay Relapse in AAV Patients, Phase 3 Trial Suggests
A combination of belimumab plus standard maintenance treatment is no better than standard of care alone at delaying relapse in ANCA-associated vasculitis (AAV) patients in remission, a Phase 3 clinical trial shows. However, a subgroup of patients who receive Rituxan (rituximab) as an induction treatment may benefit from belimumab maintenance, the…